UT Horizon Fund has participated in a $2m series A for medical device manufacturer Alafair Biosciences.

Alafair Biosciences, a US-based medical device company, has raised $2m in its series A round led by VC firm ATP Fund with participation from UT Horizon Fund, University of Texas system’s venturing fund. 

Alafair’s total funding is now $5.9m. It recently announced US regulatory clearance of its first product, VersaWrap Tendon Protector.

Julie Goonewardene, associate vice-chancellor for innovation and strategic investment and managing director for the UT Horizon Fund, said: “The UT Horizon Fund’s investment in Alafair is part of an amazing story, in which discoveries born in the lab at UT Austin have grown into a technology platform that is set to make a difference in the lives of people here in Texas and beyond.”